Jodie M. Fleming

Jodie M. Fleming

Auto-generated profile, based on publicly available information

Jodie M. Fleming

Department of Biological and Biomedical Sciences, North Carolina Central University, Durham, NC, 27707, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMatthew J. Meyer
Matthew J. Meyer
JFJodie M. Fleming
Jodie M. Fleming
ALAmy F. Lin
Amy F. Lin
SHS. Amal Hussnain
S. Amal Hussnain
EGErika Ginsburg
Erika Ginsburg
BVBarbara K. Vonderhaar
Barbara K. Vonderhaar
Defining the populations of tumor-initating cells that are present in tumors is a first step in developing therapeutics to target these cells. We show here that both CD44posCD24neg and CD44posCD24pos cell populations in estrogen receptor (ER) α–negative breast tumors are tumorigenic in murine xenograft models. We also describe a third population of xenograft-initiating cells (XIC) enriched in CD44posCD49fhiCD133/2hi cells that display heightened tumorigenicity, self-renewal in vivo, and the capacity to give rise to functional and molecular heterogeneity. Consistent with their capacity for self-renewal, these cells express elevated levels of Sox2, Bmi-1, and/or Nanog and their CpG islands are hypermethylated relative to nontumorigenic cells. These differences in methylome regulation may be responsible for the dramatic functional differences between the two populations. The identification of CD44posCD49fhiCD133/2hi XIC in ER-negative tumors may lead to expanded understanding of these tumors and ultimately the development of therapeutics designed to specifically target the cells. Cancer Res; 70(11); 4624–33. ©2010 AACR.

11 November 2009 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
MMMatthew J Meyer
Matthew J Meyer
JFJodie M Fleming
Jodie M Fleming
MAMustapha A Ali
Mustapha A Ali
MPMitchell W Pesesky
Mitchell W Pesesky
EGErika Ginsburg
Erika Ginsburg
BVBarbara K Vonderhaar
Barbara K Vonderhaar
Introduction: The invasive, mesenchymal phenotype of CD44posCD24neg breast cancer cells has made them a promising target for eliminating the metastatic capacity of primary tumors. It has been previously demonstrated that CD44neg/lowCD24pos breast cancer cells lack the ability to give rise to their invasive CD44posCD24neg counterpart. Here we demonstrate that noninvasive, epithelial-like CD44posCD24pos cells readily give rise to invasive, mesenchymal CD44posCD24neg progeny in vivo and in vitro. This interconversion was found to be dependent upon Activin/Nodal signaling. Methods: Breast cancer cell lines were sorted into CD44posCD24pos and CD44posCD24neg populations to evaluate their progeny for the expression of CD44, CD24, and markers of a mesenchymal phenotype. The populations, separated by fluorescence activated cell sorting (FACS) were injected into immunocompromised mice to evaluate their tumorigenicity and invasiveness of the resulting xenografts. Results: CD24 expression was dynamically regulated in vitro in all evaluated breast cancer cell lines. Furthermore, a single noninvasive, epithelial-like CD44posCD24pos cell had the ability to give rise to invasive, mesenchymal CD44posCD24neg progeny. Importantly, this interconversion occurred in vivo as CD44posCD24pos cells gave rise to xenografts with locally invasive borders as seen in xenografts initiated with CD44posCD24neg cells. Lastly, the ability of CD44posCD24pos cells to give rise to mesenchymal progeny, and vice versa, was blocked upon ablation of Activin/Nodal signaling. Conclusions: Our data demonstrate that the invasive, mesenchymal CD44posCD24neg phenotype is under dynamic control in breast cancer cell lines both in vitro and in vivo. Furthermore, our observations suggest that therapies targeting CD44posCD24neg tumor cells may have limited success in preventing primary tumor metastasis unless Activin/Nodal signaling is arrested.

5 September 2014 in Toxins
Verified
Journal Article
Open access
PDF file
BSBradley Stiles
Bradley Stiles
KPKisha Pradhan
Kisha Pradhan
JFJodie M. Fleming
Jodie M. Fleming
RSRamar Perumal Samy
Ramar Perumal Samy
Holger BarthHolger Barth
Holger Barth
Michel PopoffMichel Popoff
Michel Popoff
Some pathogenic spore-forming bacilli employ a binary protein mechanism for intoxicating the intestinal tracts of insects, animals, and humans. These Gram-positive bacteria and their toxins include Clostridium botulinum (C2 toxin), Clostridium difficile (C. difficile toxin or CDT), Clostridium perfringens (ι-toxin and binary enterotoxin, or BEC), Clostridium spiroforme (C. spiroforme toxin or CST), as well as Bacillus cereus (vegetative insecticidal protein or VIP). These gut-acting proteins form an AB complex composed of ADP-ribosyl transferase (A) and cell-binding (B) components that intoxicate cells via receptor-mediated endocytosis and endosomal trafficking. Once inside the cytosol, the A components inhibit normal cell functions by mono-ADP-ribosylation of globular actin, which induces cytoskeletal disarray and death. Important aspects of each bacterium and binary enterotoxin will be highlighted in this review, with particular focus upon the disease process involving the biochemistry and modes of action for each toxin.

25 June 2010 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
JFJodie M. Fleming
Jodie M. Fleming
TMTyler C. Miller
Tyler C. Miller
MMMatthew J. Meyer
Matthew J. Meyer
EGErika Ginsburg
Erika Ginsburg
BVBarbara K. Vonderhaar
Barbara K. Vonderhaar

25 June 2015 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
MDMonica D’aRcy
Monica D’aRcy
JFJodie Fleming
Jodie Fleming
WRWhitney R. Robinson
Whitney R. Robinson
EKErin L. Kirk
Erin L. Kirk
CPCharles M Perou
Charles M Perou
MTMelissa A. Troester
Melissa A. Troester

11 December 2017 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
HPHumberto Parada
Humberto Parada
XSXuezheng Sun
Xuezheng Sun
JFJodie M. Fleming
Jodie M. Fleming
CWClarLynda R. Williams-DeVane
ClarLynda R. Williams-DeVane
EKErin L. Kirk
Erin L. Kirk
MTMelissa A. Troester
Melissa A. Troester
We examined racial differences in the expression of eight genes and their associations with risk of recurrence among 478 white and 495 black women who participated in the Carolina Breast Cancer Study Phase 3. Breast tumor samples were analyzed for PAM50 subtype and for eight genes previously found to be differentially expressed by race and associated with breast cancer survival: ACOX2, MUC1, FAM177A1, GSTT2, PSPH, PSPHL, SQLE, and TYMS. The expression of these genes according to race was assessed using linear regression and each gene was evaluated in association with recurrence using Cox regression. Compared to white women, black women had lower expression of MUC1, a suspected good prognosis gene, and higher expression of GSTT2, PSPHL, SQLE, and TYMS, suspected poor prognosis genes, after adjustment for age and PAM50 subtype. High expression (greater than median versus less than or equal to median) of FAM177A1 and PSPH was associated with a 63% increase (hazard ratio (HR) = 1.63, 95% confidence interval (CI) = 1.09–2.46) and 76% increase (HR = 1.76, 95% CI = 1.15–2.68), respectively, in risk of recurrence after adjustment for age, race, PAM50 subtype, and ROR-PT score. Log2-transformed SQLE expression was associated with a 20% increase (HR = 1.20, 95% CI = 1.03–1.41) in recurrence risk after adjustment. A continuous multi-gene score comprised of eight genes was also associated with increased risk of recurrence among all women (HR = 1.11, 95% CI = 1.04–1.19) and among white (HR = 1.14, 95% CI = 1.03–1.27) and black (HR = 1.11, 95% CI = 1.02–1.20) women. Racial differences in gene expression may contribute to the survival disparity observed between black and white women diagnosed with breast cancer.